Table 2.
Univariate analysis and multivariate analysis of risk factors for EBV-DNA positive, EBER-1 positive in IBD patients
| EBV-DNA positive in blood |
EBER-1 positive in mucosa |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis |
Multivariate analysis |
Univariate analysis |
Multivariate analysis |
|||||||||
| OR | 95% CI | P | OR | 95% CI | P | OR | 95% CI | P | OR | 95% CI | P | |
| Age ≥60 years | 4.424 | 2.354-8.312 | <0.01 | 4.535 | 2.356-8.729 | <0.01 | 4.000 | 1.066-15.012 | 0.40 | 4.603 | 1.005-21.093 | 0.049 |
| Male gender | 1.445 | 0.783-2.669 | 0.239 | - | - | - | 0.441 | 0.101-1.930 | 0.277 | - | - | |
| UC | 1.689 | 0.934-3.052 | 0.083 | - | - | - | 3.750 | 1.114-12.640 | 0.033 | 6.616 | 1.410-31.040 | 0.017 |
| Clinical disease activities*:severe | 1.935 | 1.020-3.638 | 0.041 | 1.468 | 0.732-2.940 | 0.280 | 0.857 | 0.246-9.963 | 0.875 | - | - | - |
| The degree of intestinal mucositis:severe | 1.201 | 0.665-2.171 | 0.370 | - | - | - | 3.167 | 0.958-10.467 | 0.059 | - | - | - |
| 5-ASA | 0.918 | 0.460-2.092 | 0.904 | - | - | - | 0.000 | 0.000 | 0.999 | - | - | - |
| GS | 0.840 | 0.463-1.524 | 0.625 | - | - | - | 0.455 | 0.141-1.467 | 0.187 | - | - | - |
| AZA | 2.052 | 1.119-3.764 | 0.020 | 2.020 | 1.030-3.962 | 0.041 | 4.615 | 1.228-17.341 | 0.024 | 7.668 | 1.515-38.826 | 0.014 |
| IFX | 1.584 | 0.445-5.516 | 0.439 | - | - | - | 1.462 | 0.123-17.318 | 0.764 | - | - | - |
| IFX + AZA | 1.696 | 0.371-7.745 | 0.515 | - | - | - | 1.243E+9 | 0.000 | 0.999 | - | - | - |
EBV, Epstein-Barr virus; EBER-1, Epstein-Barr virus-encoded small-RNA 1; UC, ulcerative colitis; 5-ASA, 5-aminosalicylates; CS, corticosteroids; AZA, azathioprine; IFX, infliximab; IFX+AZA, infliximab in combination with azathioprine, all patients. *Clinical disease activities: the Mayo Clinic score for ulcerative colitis (UC), Crohn’s disease activity index for Crohn’s disease (CD)